Importance of leuprolide acetate variable dosing for precocious puberty: A range of acceptable suppression

Journal of Pediatric Endocrinology and Metabolism

Volumn 22, Issue 7, 2009, Pages 629-634

  Cohen, Daniela ^a,b   Janfaza, Mona ^b   Klein, Karen O ^a,b,c  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MC 5103 ^*  (United States)

Author keywords

Bioestradiol; Bone age advance; Leuprolide; Luteinizing hormone; Precocious puberty; Predicted height

Indexed keywords

ESTRADIOL; LEUPRORELIN; LUTEINIZING HORMONE;

ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE AGE; BONE MATURATION; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE DURATION; DRUG DOSE REDUCTION; ESTRADIOL BLOOD LEVEL; FEMALE; GROWTH RATE; HORMONAL REGULATION; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; OUTCOME ASSESSMENT; PRECOCIOUS PUBERTY; PREDICTION; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT DURATION;

EID: 69949179144     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2009.22.7.629     Document Type: Article

References (16)

1. Eugster EA. Precocious puberty. J Clin Endocrinol Metab 2006; 91: 15A-16A.
2. Pace JN, Miller JL, Rose LI. GnRH agonists: gonadorelin, leuprolide and nafarelin. Am Fam Physician 1991; 44: 1777-1782.
3. Kaplan SL, Grumbach MM. Clinical Review 14: Pathophysiology and treatment of sexual precocity. J Clin Endocrinol Metab 1990; 71: 785-789
4. Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994; 45: 391-405.
5. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB. Increased adult height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001; 86: 4711-4716.
6. Wilson AC, Meethal SV, Atwood CS. Leuprolide acetate: a drug of diverse clinical applications. Exp Opin Investig Drugs 2007; 16: 1851-1863.
7. Kappy MS, Stuart TE, Perelman AH, Clemons RD. Suppression of gonadotropin acetate by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron depot) in children with precocious puberty. J Clin Endocrinol Metab 1989; 69: 1087-1089.
8. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, Wintergerst K, Chi C, Klein KO, Neely EK. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006; 91: 1862-1867.
9. Kunz GJ, Sherman TI, Klein KO. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment? J Pediatr Endocrinol Metab 2007; 20: 1189-1198.
10. nd Ed. New York, NY: Appleton-Century-Crofts, 1966.
11. nd Ed. Stanford, CA: Stanford University Press, 1959.
12. Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 1994; 94: 2475-2480. (Pubitemid 24379624)
13. Lampit M, Golander A, Guttmann H, Hochberg Z. Estrogen mini-dose replacement during GnRH agonist therapy in central precocious puberty: a pilot study. J Clin Endocrinol Metab 2002; 87: 687-690. (Pubitemid 34158238)
14. Styne DM, Harris DA, Egli CA, et al. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis. J Clin Endocrinol Metab 1985; 61: 142-151.
15. Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 1986; 7: 24-33.
16. Brito VN, Latronico AC, Cukier P, Teles MG, Silveira LF, Arnhold IJ, Mendonca BB. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab 2008; 93: 2662-2669. (Pubitemid 352008534)